|
CA2321026A1
(en)
*
|
1998-03-09 |
1999-09-16 |
Zealand Pharmaceuticals A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
US7550425B2
(en)
|
2000-06-16 |
2009-06-23 |
Zealand Pharma A/S |
Diuretic peptide conjugates
|
|
WO2006045503A1
(en)
|
2004-10-19 |
2006-05-04 |
Lonza Ag |
Method for solid phase peptide synthesis
|
|
EP2295451A1
(en)
|
2005-05-04 |
2011-03-16 |
Zealand Pharma A/S |
Glucagon-like-peptide (GLP-2) analogues
|
|
GB0514071D0
(en)
|
2005-07-07 |
2005-08-17 |
Zealand Pharma As |
N- or C- terminally modified small peptides
|
|
US20090171097A1
(en)
*
|
2005-11-22 |
2009-07-02 |
Hiroshi Sugiyama |
Automated solid phase synthesis of pyrrole-imidazole polyamide
|
|
PL1966130T3
(pl)
|
2005-12-23 |
2014-05-30 |
Zealand Pharma As |
Zmodyfikowane związki mimetyczne lizyny
|
|
EP1991560B1
(en)
*
|
2006-02-20 |
2018-04-04 |
Ewha University-Industry Collaboration Foundation |
Peptide having cell membrane penetrating activity
|
|
AU2007232742B2
(en)
*
|
2006-03-29 |
2012-02-02 |
Glytech, Inc. |
Method for production of peptide thioester compound
|
|
CN101573376B
(zh)
|
2006-11-08 |
2013-11-06 |
西兰制药公司 |
选择性胰高血糖素样肽-2（glp-2）类似物
|
|
WO2008152403A1
(en)
|
2007-06-15 |
2008-12-18 |
Zealand Pharma A/S |
Glucagon analogues
|
|
JP5635532B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
ES2439499T3
(es)
|
2008-12-15 |
2014-01-23 |
Zealand Pharma A/S |
Análogos de glucagón
|
|
DK2370460T3
(da)
|
2008-12-15 |
2014-08-04 |
Zealand Pharma As |
Glucagon analoger
|
|
JP5635529B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
KR101809024B1
(ko)
|
2009-07-13 |
2017-12-14 |
질랜드 파마 에이/에스 |
아실화 글루카곤 유사체
|
|
MX343360B
(es)
|
2010-04-27 |
2016-11-03 |
Zealand Pharma As |
Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
|
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
BR112012033225A2
(pt)
|
2010-06-24 |
2017-06-20 |
Zealand Pharma As |
análogos do glucagon
|
|
SG192038A1
(en)
|
2011-01-20 |
2013-08-30 |
Zealand Pharma As |
Combination of acylated glucagon analogues with insulin analogues
|
|
KR20140100947A
(ko)
|
2011-11-03 |
2014-08-18 |
질랜드 파마 에이/에스 |
Ｇｌｐ-1 수용체 효능제 펩타이드 가스트린 접합체들
|
|
IN2014CN04401A
(enExample)
|
2011-12-23 |
2015-09-04 |
Zealand Pharma As |
|
|
WO2013098408A1
(en)
|
2011-12-30 |
2013-07-04 |
Zealand Pharma A/S |
Glucagon and cck receptor agonist peptide conjugates
|
|
AR089860A1
(es)
|
2012-02-03 |
2014-09-24 |
Zealand Pharma As |
Analogos de la grelina
|
|
CA2872315A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
|
AU2013255751B2
(en)
|
2012-05-03 |
2017-10-05 |
Zealand Pharma A/S |
GIP-GLP-1 dual agonist compounds and methods
|
|
CN109456400A
(zh)
|
2012-07-23 |
2019-03-12 |
西兰制药公司 |
胰高血糖素类似物
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
KR101990341B1
(ko)
|
2013-03-12 |
2019-06-19 |
몰레큘러 템플레이츠, 인코퍼레이션. |
세포 내재화를 유도하기 위한 ｃｄ20-결합 면역독소 및 이의 사용 방법
|
|
US9695214B2
(en)
|
2013-03-15 |
2017-07-04 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
US9169287B2
(en)
|
2013-03-15 |
2015-10-27 |
Massachusetts Institute Of Technology |
Solid phase peptide synthesis processes and associated systems
|
|
WO2014147124A1
(en)
|
2013-03-21 |
2014-09-25 |
Sanofi-Aventis Deutschland Gmbh |
Synthesis of hydantoin containing peptide products
|
|
EP2976325B1
(en)
|
2013-03-21 |
2017-03-01 |
Sanofi-Aventis Deutschland GmbH |
Synthesis of cyclic imide containing peptide products
|
|
AP2016009212A0
(en)
|
2013-10-17 |
2016-05-31 |
Zealand Pharma As |
Acylated glucagon analogues
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AU2014345570B2
(en)
|
2013-11-06 |
2019-01-24 |
Zealand Pharma A/S |
Glucagon-GLP-1-GIP triple agonist compounds
|
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
WO2015100246A1
(en)
|
2013-12-24 |
2015-07-02 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
JP6655017B2
(ja)
|
2014-01-27 |
2020-02-26 |
モレキュラー テンプレーツ, インク.Molecular Templates, Inc. |
Ｍｈｃクラスｉエピトープ送達ポリペプチド
|
|
EP3502134B1
(en)
|
2014-03-11 |
2020-12-16 |
Molecular Templates, Inc. |
Proteins comprising binding regions, shiga toxin a subunit effector regions, and carboxy-terminal, endoplasmic reticulum localization signal motifs
|
|
EP3872090A1
(en)
|
2014-03-11 |
2021-09-01 |
Molecular Templates, Inc. |
Proteins comprising amino-terminal proximal shiga toxin a subunit effector regions and cell-targeting immunoglobulin-type binding regions
|
|
EP3137488B1
(en)
|
2014-06-11 |
2019-01-02 |
Molecular Templates, Inc. |
Protease-cleavage resistant, shiga toxin a subunit effector polypeptides and cell-targeting molecules comprising the same
|
|
WO2015200883A2
(en)
|
2014-06-26 |
2015-12-30 |
Ossianix, Inc. |
Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds
|
|
WO2016066744A2
(en)
|
2014-10-29 |
2016-05-06 |
Zealand Pharma A/S |
Gip agonist compounds and methods
|
|
AU2015346045B2
(en)
|
2014-11-14 |
2021-08-26 |
Ossianix, Inc. |
Variable new antigen receptors (VNARs) directed against transferrin receptor (TfR) and their use
|
|
WO2016126950A1
(en)
|
2015-02-05 |
2016-08-11 |
Molecular Templates, Inc. |
Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
|
|
CN107567459B
(zh)
|
2015-03-18 |
2021-09-24 |
西兰制药公司 |
胰淀素类似物
|
|
GB201506380D0
(en)
|
2015-04-15 |
2015-05-27 |
Serodus Asa |
Materials and methods for treatment of pulmonary hypertension
|
|
KR20170137198A
(ko)
|
2015-04-16 |
2017-12-12 |
질랜드 파마 에이/에스 |
아실화된 글루카곤 유사체
|
|
LT3303373T
(lt)
|
2015-05-30 |
2020-07-10 |
Molecular Templates, Inc. |
Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės
|
|
KR20180030085A
(ko)
|
2015-07-26 |
2018-03-21 |
몰레큘러 템플레이츠, 인코퍼레이션. |
시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
US10683325B2
(en)
|
2015-09-17 |
2020-06-16 |
Massachusetts Institute Of Technology |
Methods and systems for solid phase peptide synthesis
|
|
WO2018031424A1
(en)
|
2016-08-06 |
2018-02-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
TWI784968B
(zh)
|
2016-09-09 |
2022-12-01 |
丹麥商西蘭製藥公司 |
澱粉素類似物
|
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
|
US11130793B2
(en)
|
2016-12-09 |
2021-09-28 |
Zealand Pharma A/S |
GLP-1/GLP-2 dual agonists
|
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
KR102590672B1
(ko)
|
2017-01-25 |
2023-10-18 |
몰레큘러 템플레이츠, 인코퍼레이션. |
탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
|
|
TWI791539B
(zh)
|
2017-06-16 |
2023-02-11 |
丹麥商西蘭製藥公司 |
用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
|
|
EP3704149A1
(en)
|
2017-11-02 |
2020-09-09 |
Ossianix, Inc. |
Improved tfr-selective binding peptides capable of crossing the blood brain barrier
|
|
PE20201254A1
(es)
|
2018-02-27 |
2020-11-16 |
Zp Spv 3 K/S |
Analogos de compstatina y sus usos medicos
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
US12258414B2
(en)
|
2018-06-22 |
2025-03-25 |
Ossianix, Inc. |
Anti-CD98hc VNARs for crossing the blood brain barrier and type IV VNAR libraries
|
|
EA202092684A1
(ru)
|
2018-08-27 |
2021-03-11 |
Ридженерон Фармасьютикалз, Инк. |
Применение рамановской спектроскопии для последующей очистки
|
|
WO2020056327A1
(en)
|
2018-09-14 |
2020-03-19 |
Ossianix, Inc. |
Tfr-specific binding moieties and transcytosis method to select vnars that cross cellular barriers
|
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
|
CA3127660A1
(en)
|
2019-01-23 |
2020-07-30 |
Millennium Pharmaceuticals, Inc. |
Cd38-binding proteins comprising de-immunized shiga toxin a subunit effectors
|
|
EP3914358A1
(en)
|
2019-01-23 |
2021-12-01 |
Millennium Pharmaceuticals, Inc. |
Anti-cd38 antibodies
|
|
CN113966226A
(zh)
|
2019-06-14 |
2022-01-21 |
西兰制药公司 |
双重glp1/2激动剂的药物肠胃外组合物
|
|
JP7711044B2
(ja)
|
2019-08-27 |
2025-07-22 |
セトペー エスペーベー ３ コマンディト セルスカブ |
コンプスタチン類似体及びその医学的使用
|
|
WO2021055816A1
(en)
|
2019-09-18 |
2021-03-25 |
Molecular Templates, Inc. |
Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
|
|
KR20220066095A
(ko)
|
2019-09-20 |
2022-05-23 |
질랜드 파마 에이/에스 |
Kv1.3 차단제
|
|
WO2021102445A1
(en)
|
2019-11-24 |
2021-05-27 |
Molecular Templates, Inc. |
Uses of cd20-binding molecules and additional therapeutic agents
|
|
US20230110689A1
(en)
|
2020-03-30 |
2023-04-13 |
Zealand Pharma A/S |
Agonist combination
|
|
US20230129788A1
(en)
|
2020-03-30 |
2023-04-27 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
|
US20230287051A1
(en)
|
2020-07-16 |
2023-09-14 |
Zp Spv 3 K/S |
Inhibitors of complement factor c3 and their medical uses
|
|
WO2022103769A1
(en)
|
2020-11-11 |
2022-05-19 |
Ossianix, Inc. |
High affinity human and monkey specific tfr-1 vnars
|
|
AU2021404497A1
(en)
|
2020-12-16 |
2023-06-08 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
|
CA3200525A1
(en)
|
2020-12-16 |
2022-06-23 |
Zealand Pharma A/S |
Pharmaceutical composition of glp-1/glp-2 dual agonists
|
|
US20230405088A1
(en)
|
2020-12-16 |
2023-12-21 |
Zealand Pharma A/S |
Pharmaceutical Composition of GLP-1/GLP-2 Dual Agonists
|
|
US20240316155A1
(en)
|
2021-02-18 |
2024-09-26 |
Zealand Pharma A/S |
Composition for treating short bowel syndrome
|
|
CA3213295A1
(en)
|
2021-03-17 |
2022-09-22 |
Molecular Templates, Inc. |
Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
|
|
KR20230159403A
(ko)
|
2021-03-23 |
2023-11-21 |
질랜드 파마 에이/에스 |
Kv1.3 차단제
|
|
WO2022260877A1
(en)
|
2021-06-07 |
2022-12-15 |
Ossianix, Inc. |
Shark vnars for treating covid-19
|
|
KR20240022551A
(ko)
|
2021-06-18 |
2024-02-20 |
베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 |
글루카곤 유사체 및 이의 의학적 용도
|
|
WO2023023166A1
(en)
|
2021-08-17 |
2023-02-23 |
Ossianix, Inc. |
Deimmunized vnar domains and scaffolds
|
|
EP4392054A1
(en)
|
2021-09-03 |
2024-07-03 |
Zealand Pharma A/S |
Dosage regime
|
|
IL313185A
(en)
|
2021-12-01 |
2024-07-01 |
Zealand Pharma As |
Peptide inhibitors of the interleukin-23 receptor
|
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
|
EP4604984A1
(en)
|
2022-10-18 |
2025-08-27 |
Zealand Pharma A/S |
Inhibitors
|
|
WO2024168411A1
(pt)
*
|
2023-02-15 |
2024-08-22 |
Proteimax Bio Technology Israel Ltd |
Aditivo de alimento e/ou suplemento alimentar, processo de obtenção, formulação de alimento funcional e/ou suplemento alimentar, uso
|
|
EP4471048A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
EP4471049A1
(en)
|
2023-06-01 |
2024-12-04 |
Zealand Pharma A/S |
Peptide inhibitors of interleukin-23 receptor
|
|
WO2025056677A1
(en)
|
2023-09-15 |
2025-03-20 |
Zealand Pharma A/S |
Dasiglucagon for use in the treatment of congenital hyperinsulinism
|
|
WO2025120001A1
(en)
|
2023-12-04 |
2025-06-12 |
Zealand Pharma A/S |
Amylin analogues for reducing consumption of high-fat food
|
|
TW202528338A
(zh)
|
2023-12-04 |
2025-07-16 |
丹麥商西蘭製藥公司 |
方法
|
|
WO2025248124A1
(en)
|
2024-05-31 |
2025-12-04 |
Zealand Pharma A/S |
Dapiglutide for use in treating a sub-group of subjects
|
|
US20250382332A1
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Novel alpha-factor based peptides with antifungal activity
|
|
WO2025259861A2
(en)
|
2024-06-12 |
2025-12-18 |
Invaio Sciences, Inc. |
Antimicrobial peptides against citrus greening
|